ES2720728T3 - Un marcador molecular de Plasmodium falciparum de resistencia a artemisinina - Google Patents
Un marcador molecular de Plasmodium falciparum de resistencia a artemisinina Download PDFInfo
- Publication number
- ES2720728T3 ES2720728T3 ES14833371T ES14833371T ES2720728T3 ES 2720728 T3 ES2720728 T3 ES 2720728T3 ES 14833371 T ES14833371 T ES 14833371T ES 14833371 T ES14833371 T ES 14833371T ES 2720728 T3 ES2720728 T3 ES 2720728T3
- Authority
- ES
- Spain
- Prior art keywords
- helix
- seq
- nucleic acid
- parasite
- gct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 title claims description 100
- 241000223960 Plasmodium falciparum Species 0.000 title claims description 66
- 229930101531 artemisinin Natural products 0.000 title description 96
- 229960004191 artemisinin Drugs 0.000 title description 87
- 239000003147 molecular marker Substances 0.000 title description 14
- 244000045947 parasite Species 0.000 claims abstract description 205
- 102100040487 Keratin, type I cytoskeletal 13 Human genes 0.000 claims abstract description 159
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 126
- 238000000034 method Methods 0.000 claims abstract description 112
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 108
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 105
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 105
- 241000224016 Plasmodium Species 0.000 claims abstract description 86
- 230000035772 mutation Effects 0.000 claims abstract description 76
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 72
- 241000282326 Felis catus Species 0.000 claims abstract description 13
- 238000003205 genotyping method Methods 0.000 claims abstract description 11
- 125000000539 amino acid group Chemical group 0.000 claims abstract 2
- 239000000523 sample Substances 0.000 claims description 93
- 108700028369 Alleles Proteins 0.000 claims description 74
- 238000012163 sequencing technique Methods 0.000 claims description 58
- 230000003321 amplification Effects 0.000 claims description 37
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 37
- 108020004414 DNA Proteins 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 230000002441 reversible effect Effects 0.000 claims description 27
- 238000000338 in vitro Methods 0.000 claims description 22
- 239000012472 biological sample Substances 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 20
- 230000004927 fusion Effects 0.000 claims description 15
- BLUAFEHZUWYNDE-XRNKLDBLSA-N chembl77 Chemical class C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4C31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-XRNKLDBLSA-N 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 11
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 10
- 239000003430 antimalarial agent Substances 0.000 claims description 9
- 239000011324 bead Substances 0.000 claims description 7
- 229960001962 mefloquine Drugs 0.000 claims description 7
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims description 5
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 claims description 5
- 101100519159 Arabidopsis thaliana PCR3 gene Proteins 0.000 claims description 5
- 101100519160 Arabidopsis thaliana PCR4 gene Proteins 0.000 claims description 5
- 101100519161 Arabidopsis thaliana PCR5 gene Proteins 0.000 claims description 5
- 101100519162 Arabidopsis thaliana PCR6 gene Proteins 0.000 claims description 5
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 5
- 101150102573 PCR1 gene Proteins 0.000 claims description 5
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 5
- 229960000948 quinine Drugs 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 238000009830 intercalation Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 claims 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 63
- 230000004083 survival effect Effects 0.000 description 37
- 230000008030 elimination Effects 0.000 description 24
- 238000003379 elimination reaction Methods 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 20
- 239000012634 fragment Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 201000004792 malaria Diseases 0.000 description 16
- 239000012071 phase Substances 0.000 description 16
- 102000054765 polymorphisms of proteins Human genes 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 11
- 238000000585 Mann–Whitney U test Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 101150116862 KEAP1 gene Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 210000000973 gametocyte Anatomy 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000004005 microsphere Substances 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 5
- 208000009182 Parasitemia Diseases 0.000 description 5
- 208000030852 Parasitic disease Diseases 0.000 description 5
- 229960002521 artenimol Drugs 0.000 description 5
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 description 5
- 229930016266 dihydroartemisinin Natural products 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 210000003812 trophozoite Anatomy 0.000 description 5
- 238000000729 Fisher's exact test Methods 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000001120 cytoprotective effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 108010007459 falcipain Proteins 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000007857 nested PCR Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 210000001563 schizont Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102000008836 BTB/POZ domains Human genes 0.000 description 3
- 108050000749 BTB/POZ domains Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 240000005790 Oroxylum indicum Species 0.000 description 3
- 235000012920 Oroxylum indicum Nutrition 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 241000224017 Plasmodium berghei Species 0.000 description 3
- 241000224024 Plasmodium chabaudi Species 0.000 description 3
- 241000224028 Plasmodium cynomolgi Species 0.000 description 3
- 241000223830 Plasmodium yoelii Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000003936 merozoite Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- -1 variants Proteins 0.000 description 3
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102220579865 Ceramide-1-phosphate transfer protein_D56V_mutation Human genes 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 102100028495 DNA-directed RNA polymerase II subunit RPB9 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 101000723873 Homo sapiens DNA-directed RNA polymerase II subunit RPB9 Proteins 0.000 description 2
- 101001091328 Homo sapiens Kelch-like protein 12 Proteins 0.000 description 2
- 101001045822 Homo sapiens Kelch-like protein 2 Proteins 0.000 description 2
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 description 2
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 241000223801 Plasmodium knowlesi Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000013523 data management Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000013048 microbiological method Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229950006717 piperaquine Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 101150001666 2a gene Proteins 0.000 description 1
- CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102400000011 Cytochrome b-c1 complex subunit 9 Human genes 0.000 description 1
- 101800000778 Cytochrome b-c1 complex subunit 9 Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- BJDCWCLMFKKGEE-KDTBHNEXSA-N Dihydroartemisinin (DHA) Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](O)[C@@H]4C BJDCWCLMFKKGEE-KDTBHNEXSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 102100036992 Ecto-ADP-ribosyltransferase 5 Human genes 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001024570 Homo sapiens Ecto-ADP-ribosyltransferase 5 Proteins 0.000 description 1
- 101001131829 Homo sapiens P protein Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102100034855 Kelch-like protein 12 Human genes 0.000 description 1
- 102100022120 Kelch-like protein 2 Human genes 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 241000224022 Plasmodium brasilianum Species 0.000 description 1
- 241001505483 Plasmodium falciparum 3D7 Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 241001675579 Plasmodium ovale curtisi Species 0.000 description 1
- 241001675578 Plasmodium ovale wallikeri Species 0.000 description 1
- 241000223808 Plasmodium reichenowi Species 0.000 description 1
- 241000223823 Plasmodium simium Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 241000587119 Plasmodium vivax Sal-1 Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282696 Saimiri sciureus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000003646 Spearman's rank correlation coefficient Methods 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 230000009643 growth defect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 102000058108 human KLHL12 Human genes 0.000 description 1
- 102000057909 human KLHL2 Human genes 0.000 description 1
- 102000047119 human OCA2 Human genes 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000003250 oocyst Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
- G01N2333/445—Plasmodium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904651P | 2013-11-15 | 2013-11-15 | |
| US201462062439P | 2014-10-10 | 2014-10-10 | |
| PCT/IB2014/002910 WO2015071759A1 (en) | 2013-11-15 | 2014-11-14 | A molecular marker of plasmodium falciparum artemisinin resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2720728T3 true ES2720728T3 (es) | 2019-07-24 |
Family
ID=52440720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14833371T Active ES2720728T3 (es) | 2013-11-15 | 2014-11-14 | Un marcador molecular de Plasmodium falciparum de resistencia a artemisinina |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10900093B2 (https=) |
| EP (1) | EP3068903B1 (https=) |
| JP (2) | JP6667445B2 (https=) |
| KR (1) | KR102283408B1 (https=) |
| CN (1) | CN105940115B (https=) |
| AU (1) | AU2014349828B2 (https=) |
| BR (1) | BR112016011046A2 (https=) |
| ES (1) | ES2720728T3 (https=) |
| WO (1) | WO2015071759A1 (https=) |
| ZA (1) | ZA201602703B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3497237B1 (en) | 2016-08-10 | 2022-05-04 | Institut Pasteur | Methods and reagents for detecting piperaquine-resistant plasmodium falciparum malaria |
| CN109504791A (zh) * | 2018-12-29 | 2019-03-22 | 潮州市人民医院 | 用于检测疟原虫青蒿素耐药性相关k13基因突变的试剂盒 |
| CN109897901A (zh) * | 2019-02-27 | 2019-06-18 | 四川国际旅行卫生保健中心 | 检测恶性疟原虫k13基因突变位点的特异性引物组及其应用 |
| CN109797207A (zh) * | 2019-02-27 | 2019-05-24 | 四川国际旅行卫生保健中心 | 一种检测恶性疟原虫k13基因四个抗性突变位点的方法 |
| CN112592395A (zh) * | 2020-12-11 | 2021-04-02 | 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) | 一种恶性疟原虫RIFIN重组蛋白PfRIFIN-54的构建、制备及用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5242794A (en) | 1984-12-13 | 1993-09-07 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5333675C1 (en) | 1986-02-25 | 2001-05-01 | Perkin Elmer Corp | Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Methods and kits for amplification and testing of nucleic acid sequences |
| WO1989001050A1 (en) | 1987-07-31 | 1989-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Selective amplification of target polynucleotide sequences |
| JP2650159B2 (ja) | 1988-02-24 | 1997-09-03 | アクゾ・ノベル・エヌ・ベー | 核酸増幅方法 |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US4988617A (en) | 1988-03-25 | 1991-01-29 | California Institute Of Technology | Method of detecting a nucleotide change in nucleic acids |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| CA2005589C (en) | 1988-12-16 | 2001-02-06 | Akzo Nobel Nv | Self-sustained, sequence replication system |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5494810A (en) | 1990-05-03 | 1996-02-27 | Cornell Research Foundation, Inc. | Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US6582938B1 (en) | 2001-05-11 | 2003-06-24 | Affymetrix, Inc. | Amplification of nucleic acids |
| TWI521064B (zh) * | 2007-05-28 | 2016-02-11 | 國立大學法人愛媛大學 | 用於偵測瘧原蟲之引子（二） |
| CN100535125C (zh) * | 2007-06-28 | 2009-09-02 | 中国疾病预防控制中心寄生虫病预防控制所 | 用于扩增恶性疟原虫药物抗性相关基因的多重pcr引物及方法 |
-
2014
- 2014-11-14 WO PCT/IB2014/002910 patent/WO2015071759A1/en not_active Ceased
- 2014-11-14 KR KR1020167015777A patent/KR102283408B1/ko not_active Expired - Fee Related
- 2014-11-14 BR BR112016011046A patent/BR112016011046A2/pt not_active IP Right Cessation
- 2014-11-14 EP EP14833371.9A patent/EP3068903B1/en active Active
- 2014-11-14 US US15/036,064 patent/US10900093B2/en active Active
- 2014-11-14 ES ES14833371T patent/ES2720728T3/es active Active
- 2014-11-14 JP JP2016553749A patent/JP6667445B2/ja active Active
- 2014-11-14 AU AU2014349828A patent/AU2014349828B2/en active Active
- 2014-11-14 CN CN201480062113.2A patent/CN105940115B/zh active Active
-
2016
- 2016-04-19 ZA ZA2016/02703A patent/ZA201602703B/en unknown
-
2019
- 2019-12-05 JP JP2019220442A patent/JP2020043873A/ja active Pending
-
2020
- 2020-12-16 US US17/124,478 patent/US11732312B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10900093B2 (en) | 2021-01-26 |
| US11732312B2 (en) | 2023-08-22 |
| US20210198755A1 (en) | 2021-07-01 |
| JP2020043873A (ja) | 2020-03-26 |
| EP3068903A1 (en) | 2016-09-21 |
| WO2015071759A1 (en) | 2015-05-21 |
| CN105940115B (zh) | 2021-07-06 |
| US20160289774A1 (en) | 2016-10-06 |
| CA2928014A1 (en) | 2015-05-21 |
| EP3068903B1 (en) | 2019-02-13 |
| JP2016537030A (ja) | 2016-12-01 |
| AU2014349828A1 (en) | 2016-05-26 |
| HK1225757A1 (en) | 2017-09-15 |
| JP6667445B2 (ja) | 2020-03-18 |
| KR102283408B1 (ko) | 2021-07-29 |
| ZA201602703B (en) | 2019-12-18 |
| WO2015071759A9 (en) | 2016-06-23 |
| BR112016011046A2 (pt) | 2019-01-29 |
| CN105940115A (zh) | 2016-09-14 |
| AU2014349828B2 (en) | 2021-01-28 |
| KR20160119753A (ko) | 2016-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Su et al. | Genetic linkage and association analyses for trait mapping in Plasmodium falciparum | |
| US11732312B2 (en) | Molecular marker of plasmodium falciparum artemisinin resistance | |
| Weedall et al. | Genomic diversity of the human intestinal parasite Entamoeba histolytica | |
| de Oliveira et al. | Genome-wide diversity and differentiation in New World populations of the human malaria parasite Plasmodium vivax | |
| Gandhi et al. | Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications | |
| Boyce et al. | Reuse of malaria rapid diagnostic tests for amplicon deep sequencing to estimate Plasmodium falciparum transmission intensity in western Uganda | |
| Simpalipan et al. | Global sequence diversity of the lactate dehydrogenase gene in Plasmodium falciparum | |
| Ouattara et al. | Extent and dynamics of polymorphism in the malaria vaccine candidate Plasmodium falciparum reticulocyte–binding protein homologue-5 in Kalifabougou, Mali | |
| US20250092471A1 (en) | Methods and reagents for detecting piperaquine-resistant plasmodium falciparum malaria | |
| Zhu et al. | Analysis of Pvama1 genes from China-Myanmar border reveals little regional genetic differentiation of Plasmodium vivax populations | |
| Yap et al. | Genetic polymorphism and natural selection in the C-terminal 42 kDa region of merozoite surface protein-1 (MSP-1) among Plasmodium knowlesi samples from Malaysia | |
| Basco et al. | Molecular epidemiology of malaria in Cameroon. XI. Geographic distribution of Plasmodium falciparum isolates with dihydrofolate reductase gene mutations in southern and central Cameroon. | |
| Barry | Malaria epidemiology: Insights from the genome of the malaria parasite | |
| CA2928014C (en) | Method for detecting a molecular marker of plasmodium falciparum artemisinin resistance | |
| HK1225757B (en) | A molecular marker of plasmodium falciparum artemisinin resistance | |
| Latif et al. | Genetic polymorphism and clustering of the Plasmodium cynomolgi Duffy binding protein 1 region II of recent macaque isolates from Peninsular Malaysia | |
| MacLeod | The system of genetic exchange in Trypanosoma brucei and other trypanosomatids | |
| Roper et al. | Extreme geographical fixation of variation in the Plasmodium falciparum gamete surface protein gene Pfs48/45 compared with microsatellite loci | |
| Ferdig | A Genetic Map and Recombination Parameters of the Human Malaria Parasite Plasmodium falciparum | |
| Njuabe et al. | Genetic diversity of Plasmodium falciparum and genetic profile after artemisinin-based combination therapy (ACTs) deployment in Cameroon for the management of uncomplicated malaria in Children | |
| OA19184A (en) | Methods and reagents for detecting piperaquine-resistant plasmodium falciparum malaria. | |
| Eltayeb | Molecular Characterization of Severe Plasmodium falciparum Malaria Parasitemia and Antimalarial Drug-resistance in Eastern Sudan | |
| Bright | Whole Genome Analysis of the Human Malaria Parasites Plasmodium vivax and P. falciparum | |
| Robinson et al. | Drug-Resistant Genotypes and Multi-Clonality in Plasmodium falciparum Analysed | |
| Chuquiyauri | Malaria in the Peruvian Amazon |